Can-Fite reports longer-than-expected survival in Phase III Namodenoson liver cancer trial
CANF•Phase III trial shows longer-than-expected survival
Can-Fite flagged longer-than-anticipated overall survival in its ongoing pivotal Phase III Namodenoson trial in advanced liver cancer.
Results have not been presented; the study remains blinded, so the observation does not indicate whether Namodenoson outperformed placebo.
The signal reflects the pooled study population, suggesting patients are living longer than expected under the trial’s original assumptions.
Management is evaluating moving up the planned interim analysis to compare survival between treatment groups under the statistical plan.
